{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:04Z","timestamp":1793931784472,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10549-022-06660-x","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:24:45Z","timestamp":1656951885000},"page":"569-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-7052","authenticated-orcid":false,"given":"Neelima","family":"Vidula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"issue":"3\u20134","key":"6660_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B (2015) Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer 6(3\u20134):84\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.40","journal-title":"Genes Cancer"},{"issue":"2","key":"6660_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3892\/or.2018.6496","volume":"40","author":"W Zhao","year":"2018","unstructured":"Zhao W, Kuai X, Zhou X, Jia L, Wang J, Yang X, Tian Z, Wang X, Lv Q, Wang B, Zhao Y, Huang W (2018) Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep 40(2):759\u2013766. https:\/\/doi.org\/10.3892\/or.2018.6496","journal-title":"Oncol Rep"},{"issue":"26","key":"6660_CR3","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6(26):22496\u201322512. https:\/\/doi.org\/10.18632\/oncotarget.4318","journal-title":"Oncotarget"},{"issue":"5","key":"6660_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ijc.28451","volume":"134","author":"H Lin","year":"2014","unstructured":"Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, Zhao P, Zhu J, Mao Y, Feng Z (2014) A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer 134(5):1239\u20131249. https:\/\/doi.org\/10.1002\/ijc.28451","journal-title":"Int J Cancer"},{"issue":"19","key":"6660_CR5","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/jco.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O\u2019Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 35(19):2141\u20132148. https:\/\/doi.org\/10.1200\/jco.2016.70.8297","journal-title":"J Clin Oncol"},{"issue":"19","key":"6660_CR6","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","volume":"123","author":"AJ Ocean","year":"2017","unstructured":"Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM (2017) Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer 123(19):3843\u20133854. https:\/\/doi.org\/10.1002\/cncr.30789","journal-title":"Cancer"},{"issue":"17","key":"6660_CR7","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.ccr-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM (2015) First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 21(17):3870\u20133878. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-3321","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6660_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O\u2019Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380(8):741\u2013751. https:\/\/doi.org\/10.1056\/NEJMoa1814213","journal-title":"N Engl J Med"},{"issue":"16","key":"6660_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cort\u00e9s J, O\u2019Shaughnessy J, Di\u00e9ras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"issue":"12","key":"6660_CR10","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A (2020) Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol 31(12):1709\u20131718. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.004","journal-title":"Ann Oncol"},{"issue":"4","key":"6660_CR11","first-page":"GS1","volume":"82","author":"I Krop","year":"2022","unstructured":"Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos K, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A (2022) Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study. Cancer Res 82(4):GS1-05","journal-title":"Cancer Res"},{"issue":"9","key":"6660_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O\u2019Shaughnessy J, Cortes J, Tsai M, Vahdat L, Di\u00e9ras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncology 32(9):1148\u20131156. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002","journal-title":"Ann Oncology"},{"issue":"3","key":"6660_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","volume":"132","author":"LJ Esserman","year":"2012","unstructured":"Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van\u2019t Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657). Breast Cancer Res Treat 132(3):1049\u20131062. https:\/\/doi.org\/10.1007\/s10549-011-1895-2","journal-title":"Breast Cancer Res Treat"},{"issue":"26","key":"6660_CR14","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/jco.2011.39.2779","volume":"30","author":"LJ Esserman","year":"2012","unstructured":"Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van \u2019t Veer L, Hylton N, (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL\u2013CALGB 150007\/150012, ACRIN 6657. J Clin Oncol 30(26):3242\u20133249. https:\/\/doi.org\/10.1200\/jco.2011.39.2779","journal-title":"J Clin Oncol"},{"issue":"7403","key":"6660_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346\u2013352. https:\/\/doi.org\/10.1038\/nature10983","journal-title":"Nature"},{"issue":"1","key":"6660_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (Oxford, England) 8(1):118\u2013127. https:\/\/doi.org\/10.1093\/biostatistics\/kxj037","journal-title":"Biostatistics (Oxford, England)"},{"issue":"2","key":"6660_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506\u2013519. https:\/\/doi.org\/10.1016\/j.cell.2015.09.033","journal-title":"Cell"},{"key":"6660_CR18","unstructured":"GeneCards\u2014the human gene database. www.genecards.org (accessed April 29, 2022)."},{"key":"6660_CR19","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, B\u00f8rresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7:11479. https:\/\/doi.org\/10.1038\/ncomms11479","journal-title":"Nat Commun"},{"key":"6660_CR20","unstructured":"NCI Clinical Trials Using Sacituzumab Govitecan. https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/intervention\/sacituzumab-govitecan. Accessed 29 Apr 2022"},{"key":"6660_CR21","unstructured":"NCT03901339. Study of Sacituzumab Govitecan-hziy versus treatment of physician\u2019s choice in participants with HR+\/HER2- metastatic breast cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03901339 (accessed April 29, 2022)"},{"issue":"5","key":"6660_CR22","doi-asserted-by":"publisher","first-page":"e96993","DOI":"10.1371\/journal.pone.0096993","volume":"9","author":"F Ambrogi","year":"2014","unstructured":"Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E, Alberti S (2014) Trop-2 is a determinant of breast cancer survival. PLoS ONE 9(5):e96993. https:\/\/doi.org\/10.1371\/journal.pone.0096993","journal-title":"PLoS ONE"},{"issue":"16","key":"6660_CR23","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1158\/1078-0432.ccr-15-1701","volume":"22","author":"E Guerra","year":"2016","unstructured":"Guerra E, Trerotola M, Tripaldi R, Aloisi AL, Simeone P, Sacchetti A, Relli V, D\u2019Amore A, La Sorda R, Lattanzio R, Piantelli M, Alberti S (2016) Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors. Clin Cancer Res 22(16):4197\u20134205. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1701","journal-title":"Clin Cancer Res"},{"issue":"29","key":"6660_CR24","doi-asserted-by":"publisher","first-page":"47052","DOI":"10.18632\/oncotarget.16789","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Teng S, Zhang Y, Zhang W, Zhang X, Xu K, Yao H, Yao J, Wang H, Liang X, Hu Z (2017) TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K\/AKT pathway and inducing EMT. Oncotarget 8(29):47052\u201347063. https:\/\/doi.org\/10.18632\/oncotarget.16789","journal-title":"Oncotarget"},{"issue":"6","key":"6660_CR25","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3892\/ijmm.2019.4378","volume":"44","author":"G Tang","year":"2019","unstructured":"Tang G, Tang Q, Jia L, Chen Y, Lin L, Kuai X, Gong A, Feng Z (2019) TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K\/Akt signaling pathway. Int J Mol Med 44(6):2161\u20132170. https:\/\/doi.org\/10.3892\/ijmm.2019.4378","journal-title":"Int J Mol Med"},{"issue":"2","key":"6660_CR26","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3892\/mmr.2018.9083","volume":"18","author":"QZ Gu","year":"2018","unstructured":"Gu QZ, Nijiati A, Gao X, Tao KL, Li CD, Fan XP, Tian Z (2018) TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K\/AKT signaling. Mol Med Rep 18(2):1782\u20131788. https:\/\/doi.org\/10.3892\/mmr.2018.9083","journal-title":"Mol Med Rep"},{"issue":"1","key":"6660_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5604\/16652681.1184223","volume":"15","author":"K Sawanyawisuth","year":"2016","unstructured":"Sawanyawisuth K, Tantapotinan N, Wongkham C, Riggins GJ, Kraiklang R, Wongkham S, Puapairoj A (2016) Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol 15(1):71\u201381. https:\/\/doi.org\/10.5604\/16652681.1184223","journal-title":"Ann Hepatol"},{"issue":"12","key":"6660_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/fon-2020-0163","volume":"16","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marm\u00e9 F, Hong Q, Delaney RJ, Hafeez A, Andr\u00e9 F, Schmid P (2020) TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2- metastatic breast cancer. Future Oncol (London, England) 16(12):705\u2013715. https:\/\/doi.org\/10.2217\/fon-2020-0163","journal-title":"Future Oncol (London, England)"},{"key":"6660_CR29","unstructured":"NCT03901339. Study of IMMU-132 in HR+\/HER2- MBC (TROPICS-02). https:\/\/www.cancergov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2019-03005&loc=0&q=sacituzumab&rl=2&t=C4872 (accessed July 13, 2020)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06660-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:27:09Z","timestamp":1657844829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06660-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6660"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06660-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NV: Research support (not related to this work) for clinical trials to the institution (MGH): Pfizer, Daehwa, Radius, Merck, Novartis. Advisory Board participation (single session,\u00a0not related to this work): OncoSec, AbbVie, and Gilead. CY: Research funding (not related to this work) to the institution (UCSF): NCI and Quantum Leap Healthcare Collaborative.HSR: Research support (not related to this work) for clinical trials through the University of California: Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Astra Zeneca, OBI, Gilead, Ayala. Honoraria (not related to this work): Puma, Samsung, Napo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Institutional Review Board review and consent of patients was not required for this study as it involved analysis of publically available de-identified datasets.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}